image header

News Releases

News Releases

Nov 8, 2022

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more

Nov 3, 2022

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting Read more

Nov 2, 2022

ALX Oncology Announces Upcoming Investor Conference Participation Read more

Oct 31, 2022

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept Read more

Oct 5, 2022

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting Read more

Sep 21, 2022

ALX Oncology to Participate in the Cantor Oncology, Hematology & HemeOnc Conference Read more

Sep 1, 2022

ALX Oncology Announces Upcoming Investor Conference Participation Read more

Aug 15, 2022

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer Read more

Aug 11, 2022

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer Read more

Aug 8, 2022

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights Read more

Displaying 1 - 10 of 21